Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

9. BIBLIOGRAFÍA Al-Ali H K, Heinrich M C, Lange T, Krahl R, Mueller M, Müller C, Niederwieser D1, Druker B J, and Deininger M W N. High incidence of BCR-ABL kinase domain mutations and absence of mutations of the PDGFR and KIT activation loops in CML patients with secondary resistance to imatinib. The Hematology Journal. Vol 5; 55-60, 2004. Arteaga C L, Baselga J. Tyrosine kinase inhibitors: Why does the current process of clinical development not apply to them? Cancer cell Magazine. Vol 5. 2004 Baig SM, Rabbi F, Hameed U, Qureshi JA, Mahmood Z, Bokhari SH, Kiani A. Molecular characterization of mutations causing β-thalassemia in Faisalabad Pakistan using the amplification refractory mutation system (ARMS-PCR). Indian Journal of Human Genetics. Vol. 11, No.2. 2005. Braziel Rita M, Shipp Margaret A, Feldman Andrew L, EspinaVirginia, Winters Mary Jaffe Elaine S, Petricoin Emanuel F, Liotta Lance A. Molecular Diagnostics. American Society of Hematology, 2003. Calabretta Bruno, Perroti Danilo. The biology of CML blast crisis. Blood Journals, Vol. 103, No. 11, 2004. Castuma Celina E, Huang Ruiping, Kornberg Arthur, Reusch Rosetta N. Inorganic Polyphosphates in the Acquisition of Competence in Escherichia Coli. The American Society for Biochesmistry and Molecular Biology. Journal of Biological Chemistry. Vol. 270, No. 22: 12980-12983, 1995. Chen Qiaofang, Lu Pin, Jones Amy V, Cross Nicholas CP, Silver Richard T, Wang Y Lynn. Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation inChronic Myeloproliferative Disorders. Journal of Molecular Diagnostics, Vol. 9, No. 2, April 2007. Cervero Ceballos Eduardo E. Desarrollo de resistencia molecular a imatinib. Aspectos moleculares de la Leucemia Mieloide Crónica. Gaceta Médica de México. Vol. 139, No. 2. 2003.

71

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Cools Jan, Stover Elizanbeth H., Boulton Christina L., et al. PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFR_-induced myeloproliferative disease. Cancer cell Magazine. Vol 3. 2003. Cortés Jorge. New molecular targets for the Treatment for the CML. . Aspectos moleculares de la Leucemia Mieloide Crónica. Gaceta Médica de México. Vol. 139, No. 2. 2003. Deininger Michael W N. Imatinib, an overview. Haematologica reports; Vol.8:20-27, 2005. Deininger Michael W N. .Novel agents for chronic myeloid leukemia: from imatinib to dasatinib and nilotinib: overcoming resistance. Community Oncology: Vol 3. No. 8, 2006. Deininger Michael W N. SRcircumventing imatinib resistance. Cancer Cell Journal. Agosto, 2004 A. Deininger Michael W N, McGreevey L. Detection of ABL kinase domain mutations with denaturing highperformance liquid chromatography. Nature Publishing Group. 2004 B. Deninger Michael W N, Goldman John M, Melo Junis V. The molecular biology of chronic myeloid leukemia. Blood Journal, Vol. 96, No. 10. 2000. Druker Brian J. Perspectives on the development of a molecularly targeted agent. Cancer Cell: February, Vol 1, 2002 Fermentas, Life Sciences. pUC18, Puc19: description and restriction map. [Base de datos en Internet]. [Última consulta: 20 de marzo de 2009]. Disponible en: http://www.fermentas.com/techinfo/nucleicacids/mappuc1819.htm Ferrari G, Pastorelli R, Buchi F, Spinelli E, Gozzini A, Bosi A, Santini V. Comparative Proteomic Analysis of Chronic Myelogenous Leukemia Cells: Inside the Mechanism of Imatinib Resistance. Journal of Proteome Research. Vol. 6, 367-375. 2007. GenBank accession. [Base de datos en internet] [Última consulta: 28 de diciembre de 2008]. Disponible en: http://www.ncbi.nlm.nih.gov/Genbank

72

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Goldman John M. Chronic Myeloid Leukemia. Leukemia, The Medicine Publushing Company. 2004. Gordois A, Schuffham P, Warren E, Ward S. Cost-utility analysis of imatinib mesilate for the treatment of advanced stage chronic myeloid leukemia. British Journal of Cancer. Vol. 89: 634-640, 2003. Gorre M, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao P N, Sawyers C L. Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification. Science, vol. 293, 2001. Gratwohl Alois, Baldomero Helen, Schwendener Alvin, Gratwohl Michael, Apperley Jane, Niederwieser Dierger. Predictability of hematopoietic stem cell transplantation rates. The Hematology Journal. Vol. 92, No. 12, 2007. Gupta Vikas, Sehajpal PK. Rapid detection of single nucleotide (-308) polymorphism in TNF-α promoter using ARMS-PCR. Current Science. Vol. 85, No. 11, 2003. Hurtado Monroy Rafael. Aspectos moleculares de la Leucemia Mieloide Crónica. Gaceta Médica de México. Vol. 139 No. 2. 2003. Jame Abraham. New BCR-ABL tyrosine kinase inhibitors for imatinib-resistant leukemia. Comunity Oncology. Vol 4. No. 1. 2007.

Jones Amy V, Kreil Sebastian, Zoi Katerina, Waghorn Katherine, Curtis Claire, Zhang Lingyan, Score Jonathan. Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. Blood, Vol. 106, No. 6, 2005. Kabarowski Janusz HS, Witte Owen N. Consequences of BCR-ABL Expression within the Hematopoietic Stem Cell in Chronic Myeloid Leukemia. Stem Cells, Vol 18: 399-408, 2000. Karhukorpi Jari, Laitinen Tarja, Karttunen Riitta, Tiilikainen Anja S. The functionally important IL-10 promoter polymorphism (-1082GA) is not a major genetic regulator in recurrent spontaneous abortions. Molecular Human Reproduction. Vol. 7, No. 2: 201-203, 2001.

73

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Kharas Michael G, Fruman David A. ABL Oncogenes and Phosphoinositide 3-Kinase: Mechanism of Activation and Downstream Effectors. Cancer Research Journal, Vol. 65, No. 6, March 2005. Laurent Eunice, Talpaz Moshe, Kantarjian Hagop, Kurzrock Razelle. The BCR Gene and Philadelphia Chromosome-positive Leukemogenesis. Cancer Research, Vol. 61: 2343-2355, 2001. Li Baogui, Khana Ashwani, Sharma Vijay, Singh Tejinder, Suthanthiran M. TGF-β1 DNA Polymorphism, Protein Levels and Blood Pressure. American Heart Association. Hypertension, Vol. 22: 271-275. 1999. Lichtman Marshall A. Is There an Entity of Chemically Induced BCR-ABL–Positive Chronic Myelogenous Leukemia? The Oncologist, Vol. 13: 645-654, 2008. Liu W-H, Makrigiorgos G M. Sensitive and quantitative detection of mutations associated with clinical resistance too STI-571. Leukemia Research No. 27. 979-982, 2003 Lodish H, Berk A, Matsudaira P, Kaiser C A, Krieger M, Scott M P, Zipursky S L, Darnell J. Biología celular y molecular. 5a edición. Buenos Aires, Argentina. Editorial Médica Panamericana, 2005. Lorenz Michael G, Wackernagel Wilfried. Bacterial Gene Transfer by Natural Genetic Transformation in the Environment. Americal Society for Microbiology, Vol. 58, No.3: 562-602, 1994. Marcucci Guido, Perrotti Danilo, Caligiuri Michael A. Understanding the Molecular Basis of Imatinib Mesylate Therapy in Chronic Myelogenous Leukemia and the Related Mechanisms of Resistance. Clinical Cancer Research, Vol. 9: 1248–1252, April 2003. Micromedex Health Care Series. Drugs Database. Thomson Series. [Base de datos en Internet] [Última consulta: 13 de febrero de 2009]. Disponible en: www.thomsonhc.com Mughal Tariq I, Goldman John M. Chronic myeloid leukemia: why does it evolve from chronic phase to blast transformation? Frontiers in Bioscience No. 11: 198-208, January, 2006. Neil P, Shah, John M. Nicoll, Bhushan Nagar. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell Magazine. Vol. 2: Agosto, 2002.

74

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Newton CR, Graham A, Powell SJ, Summers C, Kalsheker N, Smith JC, Markham AF. Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS). Nucleic Acid Research. Vol. 17, No. 4. 1989. Nussbaum Robert L. McInnes Roderick R, Williard Huntingtong F. Genética en Medicina. 5a Edición: Editorial Elsevier Masson. España, 2007. O.Hare T, Walters DK, Deininger M WN, Druker BJ. AMN107:Tightening the grip of imatinib. Cancer Cell, Vol. 7, february, 2005 Olavarria E. Leucemia mieloide crónica: controversias terapéuticas actuales. Hematológica/ edición española. No. 90, 2005. Prochi Madon, Arundhati Athalye, Vijay Bandkar, Suresh Dhumal, Arifa Soporiwala, Firuza Parikin. Fluorescence in situ

Hybridization (FISH) – A rapid and Useful Technique for Diagnosis and

Management in Leukemia. International. Journal of Human Genetics, Vol. 3, No 3: 115-119, 2003. Raza Sahid, Ullah Khalil, Ahmed Parvez, Khan Badshah, Kamal MK. Post- transplant Outcome in Chronic Myeloid Leukemia.Journal of the College of Physicians and Surgeons Pakistan. Vol. 18, No 10: 615-619, 2008. Rodak, Bernadette F. Hematología. Fundamentos y aplicaciones clínicas. 2a edición. Buenos Aires, Argentina. Editorial Médica Panamericana, 2007. Ramírez Pablo, DiPresio John F. Therapy Options in Imatinib Failures. The Oncologist. Vol. 13: 424434, 2008. Rolfs A, Schuller I, Finckh U, Weber-Rolfs I. PCR:Clinical Diagnostics and Research. Springer –Verlag. Germany, 1992.

75

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Román José. Biología y factores pronósticos en la LMC. Servicio de Hematología, Hospital Reina Sofía, Córdoba. Enero 2007. Ruiz Argüelles Guillermo J. López Martínez B, Jaime Pérez José C. Results of an allogenic nonmyeloablative stem cell transplantation program in patients with chronic myeloid leukemia. Hematologica. Vol. 87, No. 8, 2002. Ruiz Argüelles Guillermo J. Fundamentos de Hematología. 3a edición. México DF. Editorial Médica Panamericana, 2007. Sambrook J, Fritsch EF, Maniatis T. Molecular cloning, A laboratory manual. 2th Edition. CHS Press, 1990. Sawyers Charles L.

Disabling Abl—Perspectives on Abl kinase regulationand cancer therapeutics.

Cancer cell Journal. February, 2002. Shah Neil P. Overcoming Imatinib Resistance By Using Novel ABL Kinase Inhibitors in Chronic and Advanced Phase CML. ASCO, 2005. Shah Neil P, Nicoll John M, Nagar Bruchan. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer cell. Vol. 2, 2002. Shannon Kevin M. Resistance in the land of molecular cancer therapeutics. Cancel Cell : Agosto.· Vol. 2, 2002. Smith K M, Yacobi R and Van Etten R. Autoinhibition of Bcr-Abl through Its SH3 Domain. Molecular Cell, Vol. 12, 27–37, July, 2003. Snyder Larry, Champness Wendy. Molecular Genetics of Bacteria. American Society for Microbiology Press. USA, 1994.

76

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Susan Branford, Zbigniew Rudzki, Sonya Walsh, Andrew Grigg, et al. High frequency of point mutations clustered within the adenosine triphosphate–binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. American Society of Hematology. Vol 99. No. 9. 2002. Suthanthiran Manikkam, Li Baogui, Song Jong O, Ding Ruchuang, Sharma Vijay K. Transforming growth factor-β1 hyperexpression in African-American hypertensives. A novel mediator of hypertension and/or target organ damage. PNAS. Vol. 97, No. 7: 3479-3484, 2000. Talpaz M. Shah N P. Neweer Tyrosine Kinase inhibitors for CML. Indian Journal of Medicine and Pediatric oncology. Vol 27. No. 4. 2006. Tang X, Nakata Y, Li HO, Zhang M, Gao H, Fujita A. The optimization of preparations of competent cells for transformation of E. coli. Nucleic Acid Research. Vol. 22, No. 14. 2857-2858, 1994. Tefan Lee Yen. Comparison of standard bacterial transformation protocols. Bio. 293. 2007. Traina Fabiola, Barreto José, Saad Mario, et al. BCR-ABL binds to IRS-1 and IRS-1 phosphorylation is inhibited by imatinib in K562 cells. FEBS letters. 535:17-22. 2003. Tu Zhiming, He Guangyuan, Li Kexiu X, Chen Mingjie, Chang Junli, Chen Ling, Yao Qing, Liu Dongping P. An improved system for competent cell preparation and high efficiency plasmid transformation using different cepas of Escherichia coli. Electronic Journal of Biotechnology. Vol 8. No. 1. 2005. Vallejos G, Monzón S J, Trela CM, Reyes JM. Mesilato de imatinib como alternativa terapéutica en la fase crónica de la leucemia mieloide crónica. Revista de posgrado de la VIa cátedra de Medicina, No. 166. 2007. Vargas Viveros Pablo. Evolución citogenética y molecular en pacientes tratados con imatinib. Aspectos moleculares de la Leucemia Mieloide Crónica. Gaceta Médica de México. Vol. 139, No. 2. 2003.

77

Detección de la mutación T315I de ABL1 asociada a la resistencia a imatinib, dasatinib y nilotinib

Volpe Gisella, Cignetti Alessandro, Panuzzo Cristina, Kuka Mirela, Vitaggio Katiuscia, Brancaccio Mara, Perrone Giuseppe. Alternative BCR/ABL Splice Variants in Philadelphia Chromosome–Positive Leukemias Result in Novel Tumor-Specific Fusion Proteins that May Represent Potential Targets for Immunotherapy Approaches. Cancer Research, Vol. 67, No11: Junio, 2007. You Frank, Huo Naxin, Gu Y Q, Lou MC. BatchPrimer3: A high throughput web application for PCR and sequencing primer design. BMC Bioinformatics. 9:253, 2008. Wei Yuan. Molecular monitoring of Chronic Myeloid Leukemia treated with Imatinib mesylate. [Tesis de Doctorado]. Instituto de Medicina. Göteberg University, Suecia. 2007. Weisberg E, Manley P, Cowan-Jacob S, Hochhaus A, Griffin J D. Second generation inhibitors of BCRABL for the treatment of imatinibresistant chronic myeloid leukaemia. Nature Reviews, Cancer. Vol. 7. Mayo, 2007. Willis S G, Lange T, Demehri S, Otto O, Crossman L, Niederwieser D, Stoffregen E P, McWeeney S, Kovacs I, Park B, Druker B J, and Deininger M. High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy. Blood. Vol 106 No. 6: 2128-2137, 2005. Zheng X, Güller S, Beissert T, Puccetti T and Ruthardt M. BCR and its mutants, the reciprocal t(9;22)associated ABL/BCR fusion proteins, differentially regulate the cytoskeleton and cell motility. BMC Cancer Vol. 6, No. 262. 2006. Zou Xiaming, Calame Kathryn. Signaling Pathways Activated by Oncogenic Forms of Abl Tyrosine Kinase. The Journal of Biological Chemistry. Vol. 274, No. 26: 18141-18144. 1999.

78